230 related articles for article (PubMed ID: 25382022)
21. Diffusion-weighted imaging and (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer: Correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors.
Karan B; Pourbagher A; Torun N
J Magn Reson Imaging; 2016 Jun; 43(6):1434-44. PubMed ID: 26663655
[TBL] [Abstract][Full Text] [Related]
22. [Use of 18F-FDG-positron emission tomography in presurgical evaluation of nonspecific or suspectious adrenal masses in non-oncologic patients].
Pavón-Paz I; Rosado-Sierra JA; Balsa-Bretón MÁ; Guijarro-Armas G; Merino-Viveros M; Penín-Gonzalez FJ
Med Clin (Barc); 2016 Feb; 146(3):104-7. PubMed ID: 26343158
[TBL] [Abstract][Full Text] [Related]
23. Differentiation of an adrenal mass in patients with non-small cell lung cancer by means of a normal range of adrenal standardized uptake values on FDG PET/CT.
Kim BS; Lee JD; Kang WJ
Ann Nucl Med; 2015 Apr; 29(3):276-83. PubMed ID: 25480483
[TBL] [Abstract][Full Text] [Related]
24. Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT.
Fikri AS; Kroiss A; Ahmad AZ; Zanariah H; Lau WF; Uprimny C; Donnemiller E; Kendler D; Nordin AJ; Virgolini IJ
Acta Radiol; 2014 Jun; 55(5):631-40. PubMed ID: 24037430
[TBL] [Abstract][Full Text] [Related]
25. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
26. Quantitative analysis of normal and pathologic adrenal glands with 18F-FDOPA PET/CT: focus on pheochromocytomas.
Moreau A; Giraudet AL; Kryza D; Borson-Chazot F; Bournaud C; Mognetti T; Lifante JC; Combemale P; Giammarile F; Houzard C
Nucl Med Commun; 2017 Sep; 38(9):771-779. PubMed ID: 28704339
[TBL] [Abstract][Full Text] [Related]
27. Preliminary comparison of diffusion-weighted MRI and PET/CT in predicting histological type and malignancy of lung cancer.
Liu LP; Zhang XX; Cui LB; Li J; Yang JL; Yang HN; Zhang Y; Zhou Y; Tang X; Qi S; Fang Y; Zhang J; Yin H
Clin Respir J; 2017 Mar; 11(2):151-158. PubMed ID: 25918835
[TBL] [Abstract][Full Text] [Related]
28. Texture analysis of FDG PET/CT for differentiating between FDG-avid benign and metastatic adrenal tumors: efficacy of combining SUV and texture parameters.
Nakajo M; Jinguji M; Nakajo M; Shinaji T; Nakabeppu Y; Fukukura Y; Yoshiura T
Abdom Radiol (NY); 2017 Dec; 42(12):2882-2889. PubMed ID: 28612161
[TBL] [Abstract][Full Text] [Related]
29. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET.
Schwenzer NF; Schmidt H; Gatidis S; Brendle C; Müller M; Königsrainer I; Claussen CD; Pfannenberg AC; Schraml C
J Magn Reson Imaging; 2014 Nov; 40(5):1121-8. PubMed ID: 24923481
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.
Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G
Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
32. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic performance of
Altinmakas E; Hobbs BP; Ye H; Grubbs EG; Perrier ND; Prieto VG; Lee JE; Ng CS
Abdom Radiol (NY); 2017 Feb; 42(2):577-584. PubMed ID: 27665482
[TBL] [Abstract][Full Text] [Related]
34. Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and (18)F-FDG PET.
Iizuka Y; Matsuo Y; Umeoka S; Nakamoto Y; Ueki N; Mizowaki T; Togashi K; Hiraoka M
Eur J Radiol; 2014 Nov; 83(11):2087-92. PubMed ID: 25174774
[TBL] [Abstract][Full Text] [Related]
35. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
36. Quantitative assessment of simultaneous F-18 FDG PET/MRI in patients with various types of hepatic tumors: Correlation between glucose metabolism and apparent diffusion coefficient.
Kong E; Chun KA; Cho IH
PLoS One; 2017; 12(7):e0180184. PubMed ID: 28672016
[TBL] [Abstract][Full Text] [Related]
37. Role of multi-modality functional imaging in differentiation between benign and malignant thyroid
Shi H; Yuan Z; Yang C; Zhang J; Liu C; Sun J; Ye X
Clin Transl Oncol; 2019 Nov; 21(11):1561-1567. PubMed ID: 30924093
[TBL] [Abstract][Full Text] [Related]
38. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
39. Can dual-time-point 18F-FDG PET/CT differentiate malignant salivary gland tumors from benign tumors?
Toriihara A; Nakamura S; Kubota K; Makino T; Okochi K; Shibuya H
AJR Am J Roentgenol; 2013 Sep; 201(3):639-44. PubMed ID: 23971458
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of dual-phase 18F-FDG PET/CT for diagnosing small pancreatic tumors.
Kawada N; Uehara H; Hosoki T; Takami M; Shiroeda H; Arisawa T; Tomita Y
Pancreas; 2015 May; 44(4):655-9. PubMed ID: 25815646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
